Hydroxychloroquine Associated with Favorable Cardiac Outcomes in People with Lupus
A connection exists between hydroxychloroquine (HCQ) dosage and heart health in people with lupus. The higher HCQ dose taken, the lower blood platelet activity. Platelets can lead to the development of thrombosis or blood clots in the veins, which can lead to heart conditions including heart attack.
A group of 132 people with lupus were studied and 108 were on HCQ. The amount of platelets found in the HCQ group was significantly lower, and higher dosage of the therapy (above 5 mg/kg) resulted in lower production of platelets in their blood. Overall, the HCQ group saw better vascular or heart function.
The findings support use of HCQ therapy for more favorable outcomes in people with lupus. The drug appears to offer protective benefits. Consult your physician before making any changes to your medication. Learn about how lupus affects the heart and circulation.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now